In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics

Diagn Microbiol Infect Dis. 2004 Jul;49(3):197-200. doi: 10.1016/j.diagmicrobio.2004.02.008.

Abstract

The in vitro activity of CA(1-7)M(2-9)NH(2), a 15-residue synthetic hybrid peptide derived from the sequences of cecropin A and melittin, alone and in combination with amoxicillin-clavulanate, imipenem, clarithromycin, ciprofloxacin, rifampin, and vancomycin, was investigated against 40 nosocomial isolates of methicillin-resistant Staphylococcus aureus. Antimicrobial activity of CA(1-7)M(2-9)NH(2) was measured by minimal inhibitory concentration, MBC, and time-kill studies. All isolates were inhibited at concentrations of 1 to 16 microg/mL. Combination studies performed with S. aureusATCC 43300 demonstrated synergy only when CA(1-7)M(2-9)NH(2) was combined with amoxicillin-clavulanate and imipenem. Our findings show that CA(1-7)M(2-9)NH(2) is active against methicillin-resistant S. aureusand that its activity is enhanced when it is combined with several antimicrobial agents.

Publication types

  • Comparative Study

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / pharmacology*
  • Cross Infection / drug therapy
  • Drug Interactions
  • Female
  • Humans
  • Imipenem / pharmacology*
  • Male
  • Melitten / pharmacology*
  • Methicillin Resistance*
  • Microbial Sensitivity Tests
  • Sensitivity and Specificity
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / growth & development
  • Staphylococcus aureus / isolation & purification

Substances

  • Melitten
  • Imipenem
  • Amoxicillin-Potassium Clavulanate Combination